Research & Studies
Share your love
FDA Warms 8 Companies for Unapproved Eye Items
On Monday, the US Food and Drug Administration (FDA) took action by sending warning letters to several companies, including CVS and Walgreens, due to concerns regarding the manufacturing and marketing of unapproved eye products. According to the FDA, these products…
Pioneering Glaucoma Therapy: $2M Research Grant Awarded
Researchers at Indiana University School of Medicine are embarking on a groundbreaking mission to develop a new therapy for glaucoma, a disease that can lead to blindness. This endeavor is made possible by a newly awarded five-year, $2 million R01…
Carl Zeiss Meditec to Acquire D.O.R.C.
Carl Zeiss Meditec AG announced that they have entered into an agreement to acquire 100% of the shares in D.O.R.C. Dutch Ophthalmic Research Center (International) B.V. from Eurazeo SE, based in Paris, France. The deal is worth €985 million (nearly…
Sight Sciences Applauds Medicare’s MIGS Decision
Sight Sciences expressed its support for the decision made by five Medicare Administrative Contractors to withdraw their previously announced final local coverage determinations (LCDs) for Micro-Invasive Glaucoma Surgery, originally slated to become effective on January 29, 2024. The five MACs—WPS…
RevOpsis Raises $16.5M for Wet AMD Treatment
RevOpsis Therapeutics has announced the successful closure of its first seed funding round, securing a total of $16.5 million. This funding is set to advance the development and commercialization of treatments for chronic multifactorial diseases through the company’s innovative, fully…
Eye Exams May Track Neurodegeneration in Parkinson’s
Researchers from the University of the Basque Country (UPV/EHU) and Biobizkaia have explored the potential of using a common ophthalmological tool, optical coherence tomography, to monitor neurodegeneration in patients with Parkinson’s disease. This non-invasive method, commonly employed in eye health…
LEP Biomedical Gains Funding for HyaGuard Platform
LEP Biomedical announced pre-seed funding of €100,000 ($107,000) over two 6-month periods, which the company says will allow for further preclinical milestones in the development of the HyaGuard platform. The funding was made through Enterprise Ireland. Innovative Design of HyaGuard…
SalioGen Picks SGT-1001 for Stargardt Disease Development
SalioGen Therapeutics announced the selection of SGT-1001 as a development candidate for Stargardt disease treatment, a rare inherited retinal disease. This innovative therapy, SGT-1001, is designed as a one-time, non-viral intervention aimed at slowing or halting the progressive central vision…
Phoenix-Micron Teams with ArtiKode for AI Imaging
Phoenix-Micron announced a new collaboration with ArtiKode Intelligence, a pioneering artificial intelligence (AI) and machine learning company based in Valencia, Spain. This partnership aims to advance the capabilities of the MICRON Software Suite through automated optical coherence tomography (OCT) segmentation…
Ocugen Completes Dosing in Key Trial for GA Treatment
Ocugen has officially completed dosing in the second cohort of its phase 1/2 ArMaDa trial of OCU410, a novel gene therapy designed to treat geographic atrophy (GA). The therapy, known as adeno-associated viral vector 5 human RORA (AAV5-hRORA), is being…